John R. Laird

John R. Laird

Auto-generated profile, based on publicly available information

John R. Laird

Heart and Vascular Institute, Adventist Health St. Helena, St. Helena, CA 94574, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2015 in Circulation
Verified
Journal Article
Open access
GTGunnar Tepe
Gunnar Tepe
JLJohn Laird
John Laird
PSPeter Schneider
Peter Schneider
MBMarianne Brodmann
Marianne Brodmann
PKPrakash Krishnan
Prakash Krishnan
MJMichael R. Jaff
Michael R. Jaff
Background—: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results—: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm ( P =0.82) and 25.8% and 19.5% ( P =0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P <0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm ( P <0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [ P =0.10]). There were no device- or procedure-related deaths and no major amputations. Conclusions—: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique Identifiers: NCT01175850 and NCT01566461.

1 June 2010 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
JLJohn R. Laird
John R. Laird
BKBarry T. Katzen
Barry T. Katzen
DSDierk Scheinert
Dierk Scheinert
JLJohannes Lammer
Johannes Lammer
JCJeffrey Carpenter
Jeffrey Carpenter
FIfor the RESILIENT Investigators
for the RESILIENT Investigators
Background—: Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the superficial femoral artery. There are conflicting data regarding the benefits of superficial femoral artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—: A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the superficial femoral artery and proximal popliteal artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions—: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the superficial femoral artery and proximal popliteal artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00673985.

18 January 2019 in Cancers
Verified
Journal Article
Open access
PDF file
GTGopal S. Tandel
Gopal S. Tandel
MBMainak Biswas
Mainak Biswas
OKOmprakash G. Kakde
Omprakash G. Kakde
ATAshish Tiwari
Ashish Tiwari
HSHarman S. Suri
Harman S. Suri
Jasjit SuriJasjit Suri
Jasjit Suri
A World Health Organization (WHO) Feb 2018 report has recently shown that mortality rate due to brain or central nervous system (CNS) cancer is the highest in the Asian continent. It is of critical importance that cancer be detected earlier so that many of these lives can be saved. Cancer grading is an important aspect for targeted therapy. As cancer diagnosis is highly invasive, time consuming and expensive, there is an immediate requirement to develop a non-invasive, cost-effective and efficient tools for brain cancer characterization and grade estimation. Brain scans using magnetic resonance imaging (MRI), computed tomography (CT), as well as other imaging modalities, are fast and safer methods for tumor detection. In this paper, we tried to summarize the pathophysiology of brain cancer, imaging modalities of brain cancer and automatic computer assisted methods for brain cancer characterization in a machine and deep learning paradigm. Another objective of this paper is to find the current issues in existing engineering methods and also project a future paradigm. Further, we have highlighted the relationship between brain cancer and other brain disorders like stroke, Alzheimer’s, Parkinson’s, and Wilson’s disease, leukoriaosis, and other neurological disorders in the context of machine learning and the deep learning paradigm.

9 December 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
NKNarendra N. Khanna
Narendra N. Khanna
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
VVVijay Viswanathan
Vijay Viswanathan
JFJosé Manuel Mattos Fernandes e Fernandes
José Manuel Mattos Fernandes e Fernandes
SPSudip Paul
Sudip Paul
JSJasjit S. Suri
Jasjit S. Suri
Motivation: The price of medical treatment continues to rise due to (i) an increasing population; (ii) an aging human growth; (iii) disease prevalence; (iv) a rise in the frequency of patients that utilize health care services; and (v) increase in the price. Objective: Artificial Intelligence (AI) is already well-known for its superiority in various healthcare applications, including the segmentation of lesions in images, speech recognition, smartphone personal assistants, navigation, ride-sharing apps, and many more. Our study is based on two hypotheses: (i) AI offers more economic solutions compared to conventional methods; (ii) AI treatment offers stronger economics compared to AI diagnosis. This novel study aims to evaluate AI technology in the context of healthcare costs, namely in the areas of diagnosis and treatment, and then compare it to the traditional or non-AI-based approaches. Methodology: PRISMA was used to select the best 200 studies for AI in healthcare with a primary focus on cost reduction, especially towards diagnosis and treatment. We defined the diagnosis and treatment architectures, investigated their characteristics, and categorized the roles that AI plays in the diagnostic and therapeutic paradigms. We experimented with various combinations of different assumptions by integrating AI and then comparing it against conventional costs. Lastly, we dwell on three powerful future concepts of AI, namely, pruning, bias, explainability, and regulatory approvals of AI systems. Conclusions: The model shows tremendous cost savings using AI tools in diagnosis and treatment. The economics of AI can be improved by incorporating pruning, reduction in AI bias, explainability, and regulatory approvals.

1 February 2012 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
JLJohn R. Laird
John R. Laird
BKBarry T. Katzen
Barry T. Katzen
DSDierk Scheinert
Dierk Scheinert
JLJohannes Lammer
Johannes Lammer
JCJeffrey Carpenter
Jeffrey Carpenter
MJMichael R. Jaff
Michael R. Jaff
Purpose To evaluate longer outcomes of primary nitinol stenting for the treatment of femoropopliteal lesions up to 15 cm long after these stents were found to have superior short-term patency vs. balloon angioplasty. Methods Two hundred and six patients (143 men; mean age 67 years) with intermittent claudication due to superficial femoral and proximal popliteal artery lesions were randomized (2:1) to treatment with nitinol stents or balloon angioplasty at 24 US and European centers and followed for 3 years. In that time, 15 patients died, 20 withdrew consent, and 10 were lost to follow-up, leaving 161 (78.2%) patients for 36-month assessment. Results The 12-month freedom from target lesion revascularization (TLR) was 87.3% for the stent group vs. 45.2% for the angioplasty group (p<0.0001). At 3 years, there was no difference in survival (90.0% vs. 91.7%, p=0.71) or major adverse events (75.2% vs. 75.2%, p=0.98) between the stent and angioplasty groups. Duplex ultrasound was not mandated after the first year, so stent patency could not be ascertained beyond 1 year, but freedom from TLR at 3 years was significantly better in the stent group (75.5% vs. 41.8%, p<0.0001), as was clinical success (63.2% vs. 17.9%, p<0.0001). At 18 months, a 4.1% (12/291) stent fracture rate was documented. Conclusion In this multicenter trial, primary implantation of a nitinol stent for moderate-length lesions in the femoropopliteal segment of patients with claudication was associated with better long-term results vs. balloon angioplasty alone.

24 March 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
EAEhrin J. Armstrong
Ehrin J. Armstrong
DCDebbie C. Chen
Debbie C. Chen
GWGregory G. Westin
Gregory G. Westin
SSSatinder Singh
Satinder Singh
CMCaroline E. McCoach
Caroline E. McCoach
JLJohn R. Laird
John R. Laird
Background: Current guidelines recommend that patients with peripheral arterial disease ( PAD ) cease smoking and be treated with aspirin, statin medications, and angiotensin‐converting enzyme ( ACE ) inhibitors. The combined effects of multiple guideline‐recommended therapies in patients with symptomatic PAD have not been well characterized. Methods and Results: We analyzed a comprehensive database of all patients with claudication or critical limb ischemia ( CLI ) who underwent diagnostic or interventional lower‐extremity angiography between June 1, 2006 and May 1, 2013 at a multidisciplinary vascular center. Baseline demographics, clinical data, and long‐term outcomes were obtained. Inverse probability of treatment propensity weighting was used to determine the 3‐year risk of major adverse cardiovascular or cerebrovascular events ( MACE ; myocardial infarction, stroke, or death) and major adverse limb events ( MALE ; major amputation, thrombolysis, or surgical bypass). Among 739 patients with PAD , 325 (44%) had claudication and 414 (56%) had CLI . Guideline‐recommended therapies at baseline included use of aspirin in 651 (88%), statin medications in 496 (67%), ACE inhibitors in 445 (60%), and smoking abstention in 528 (71%) patients. A total of 237 (32%) patients met all four guideline‐recommended therapies. After adjustment for baseline covariates, patients adhering to all four guideline‐recommended therapies had decreased MACE (hazard ratio [ HR ], 0.64; 95% CI , 0.45 to 0.89; P =0.009), MALE ( HR , 0.55; 95% CI , 0.37 to 0.83; P =0.005), and mortality ( HR , 0.56; 95% CI , 0.38 to 0.82; P =0.003), compared to patients receiving less than four of the recommended therapies. Conclusions: In patients with claudication or CLI , combination treatment with four guideline‐recommended therapies is associated with significant reductions in MACE , MALE , and mortality.